Patients with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC) show a significant response to checkpoint inhibitor therapies, but the economic impact of these therapies is unknown. A decision analytic model was used to explore the effectiveness and cost burden of MSI-H/dMMR mCRC treatment. METHODS: The treatment of hypothetical patients with MSI-H/dMMR mCRC was simulated in 2 treatment scenarios: a third-line treatment and an exploratory first-line treatment. The treatments compared were nivolumab, ipilimumab and nivolumab, trifluridine and tipiracil (third-line treatment), and mFOLFOX6 and cetuximab (first-line treatment). Disease progression, drug toxicity, and survival rates were based on the CheckMate 142, study of TAS-102 in patients with metastatic colorectal cancer refractory to standard chemotherapies (RECOURSE) and Cancer and Leukemia Group B/Southwest Oncology Group 80405 trials. The analyzed outcomes included survival (life-years), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). RESULTS: Ipilimumab with nivolumab was the most effective strategy (10.69 life-years and 9.25 QALYs for the third line; 10.69 life-years and 9.44 QALYs for the first line) in comparison with nivolumab (8.21 life-years and 6.76 QALYs for the third line; 8.21 life-years and 7.00 QALYs for the first line), trifluridine and tipiracil (0.74 life-years and 0.07 QALYs), and mFOLFOX6 and cetuximab (2.72 life-years and 1.63 QALYs). However, neither checkpoint inhibitor therapy was cost-effective in comparison with trifluridine and tipiracil (nivolumab ICER, $153,000; ipilimumab and nivolumab ICER, $162,700) or mFOLFOX6 and cetuximab (nivolumab ICER, $150,700; ipilimumab and nivolumab ICER, $158,700). CONCLUSIONS: This modeling analysis found that both single and dual checkpoint blockade could be significantly more effective for MSI-H/dMMR mCRC than chemotherapy, but they were not cost-effective, largely because of drug costs. Decreases in drug pricing and/or the duration of maintenance nivolumab could make ipilimumab and nivolumab costeffective. Prospective clinical trials should be performed to explore the optimal duration of maintenance nivolumab. Cancer 2019;125:278-289.
INTRODUCTION
Patients with metastatic colorectal cancer (mCRC) on third-line chemotherapy have a median overall survival of only 7 months with the newest approved agent, a combination of trifluridine and tipiracil. 1, 2 Patients with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) mCRC are even less responsive to chemotherapy, but they show promising responses to immune checkpoint inhibitors. [2] [3] [4] [5] The CheckMate 142 phase 2 trial, investigating checkpoint blockade as third-line therapy for MSI-H/dMMR mCRC, has shown dramatic results thus far, with the median duration of response not yet reached at 12 months. 3, 6, 7 Checkpoint inhibitor therapy is expensive, however, with cost estimates of $300,000/y per patient treated with ipilimumab and nivolumab combination therapy. 8 Because of the rising costs of cancer care and financial consequences for both patients and the US health care system, studies are needed to explore whether the added value of immune checkpoint inhibitors is worth the high cost.
The aims of our study of MSI-H/dMMR mCRC are 2-fold: first, to compare nivolumab with and without ipilimumab to chemotherapy in the third-line setting and extrapolate clinical data to perform a speculative analysis of these treatments in the first-line setting and, second, to investigate whether such therapies are cost-effective from a third-party payer perspective. We use a decision analytic model to estimate the unadjusted life-years (overall survival), quality-adjusted life-years (QALYs), and cost-effectiveness of nivolumab, ipilimumab and nivolumab, trifluridine and tipiracil (third-line setting), and mFOLFOX6 and cetuximab (first-line setting).
MATERIALS AND METHODS

Model Design: Third-Line Treatment
A state transition cohort, or Markov model, was constructed in TreeAge Pro (TreeAge, Williamstown, Massachusetts). The simulation in the base-case analysis began with a hypothetical cohort of 57-year-old men with MSI-H/dMMR mCRC who had progressed on 2 prior lines of chemotherapy (FOLFOX and FOLFIRI). The compared treatments were nivolumab, ipilimumab and nivolumab, and trifluridine and tipiracil. The health states included alive with disease on third-line therapy, alive with a durable response (remission) on third-line therapy, alive with disease on fourth-line therapy, alive on palliative care, and dead (Fig. 1A) . Possible causes of 
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Cancer January 15, 2019 mortality included death from complications of therapy, death from cancer, and death from all-cause age/sexrelated mortality. The Markov cycle length was 1 week. The simulated cohort was followed over a lifetime time horizon. In all treatment arms, the patient could stay in the same state with stable disease, have a durable response (remission), progress to fourth-line therapy or palliative care, die of adverse effects of therapy, die of cancer, or die of age-and sex-related mortality.
Parameter Estimates
Model parameters were estimated from the literature. Base-case values and ranges used in sensitivity analyses are summarized in Table 1 .
Model Transition Probabilities and Calibration
Overall survival and progression-free survival for all treatment arms were estimated from clinical trials. Hazard rates for patients with MSI-H/dMMR mCRC treated with nivolumab and with ipilimumab and nivolumab were estimated from the CheckMate 142 trial's Kaplan-Meier curves of overall and progression-free survival. 3, 6, 7 Early results from CheckMate 142 suggest that responders to therapy achieve a durable response, with rates of progression and cancer-related death falling to zero; this is in keeping with other large studies of immune checkpoint inhibitors. 4, 5, 10, [34] [35] [36] [37] We incorporated this phenomenon of durable response into our primary model. However, given that this finding was based on only a small number of patients thus far, we also generated a second, conservative model that assumed no durable response. For the chemotherapy comparison arm, there are no large studies of patients with MSI-H/ dMMR mCRC treated with conventional chemotherapy. Therefore, for our third-line conventional chemotherapy arm, we used data from the study of TAS-102 in patients with metastatic colorectal cancer refractory to standard chemotherapies (RECOURSE) trial, which used trifluridine and tipiracil in patients with mCRC and an undefined MSI-H/dMMR status. 1 The probability of adverse events related to drug therapy was derived from the CheckMate 142 and RECOURSE trials. 1, 3, 6, 7 The timing of adverse events for the checkpoint inhibitors was based on the published literature. [38] [39] [40] [41] For nivolumab monotherapy, we estimated that 95% of adverse events would occur between weeks 6 and 30 and that the rest of the events could occur at any time before or after. For ipilimumab and nivolumab, we estimated that 95% of the adverse events would occur between weeks 3 and 12 and that the rest of the events could occur at any time before or after. For the probability of treatment-related death, we estimated probabilities for ipilimumab and nivolumab and for nivolumab alone by pooling data from the literature (see the supporting information). [10] [11] [12] [13] [14] [15] [16] [17] [18] The probability of treatment-related death from trifluridine and tipiracil was derived from the RECOURSE trial. 1 Age-and sex-related mortality was estimated from 2012 Centers for Disease Control and Prevention life tables. 21 
Costs and Utilities
Costs were based on the published literature and converted to 2017 US dollars with the Consumer Price Index (US Bureau of Labor Statistics) and the Medicare Average Sales Price Drug Pricing File under the assumption of an average weight of 70 kg and an average body surface area of 1.86 m 2 . 31, 42 Quality-of-life measures were adjusted to utility scores for specific health states, as listed in Table 1 , along with disutilities from drug-related adverse events. For the checkpoint inhibitors, a weighted average of disutilities was estimated from the melanoma literature because of the small sample size in the CheckMate 142 trial. 10, 26, 30 The proportion of grade 1 and 2 adverse events versus grade 3 and 4 adverse events was taken from the CheckMate 142 trial. 3, 6, 7 For trifluridine and tipiracil and fourth-line chemotherapy, a weighted average of disutilities was estimated from FOLFOX and regorafenib studies. 19, 24 The proportion of grade 1 and 2 adverse events versus grade 3 and 4 adverse events for trifluridine and tipiracil was taken from the RECOURSE trial. 1 Costs and utilities were discounted at an annual rate of 3%. 43 
Outcomes
The primary outcomes of the analysis were the unadjusted life-years (overall survival), QALYs, and incremental costeffectiveness ratio (ICER) per QALY between competing treatment strategies. The primary willingness-to-pay (WTP) threshold was set at $100,000/QALY, although other values were explored in a sensitivity analysis. 44 All strategies were plotted, and an efficiency frontier was created to determine the cost-effective strategy at the WTP threshold. 45 
Analyses Performed
A base-case analysis using best estimates for all model parameters was performed. One-way deterministic sensitivity analyses were performed across a wide range of values to investigate the effects of changes in model parameters on estimated outcomes. Adverse event probabilities and costs were varied by 0 to +100% because of uncertainty in the literature. Utilities were varied across the range of values found in the published literature. In addition, we performed a probabilistic sensitivity analysis in which model parameters with available data were simultaneously varied according to assigned distributions, as shown in Table 1 . 46 Costs for the probabilistic sensitivity analysis were varied by ±20%, as in other studies. 30 
First-Line Treatment Analysis
For the speculative analysis of untreated MSI-H/dMMR mCRC, the compared treatments were ipilimumab and nivolumab, nivolumab, and mFOLFOX6 and cetuximab. The health states included alive with disease on first-line therapy, alive with a durable response on firstline therapy, alive with disease on second-line and beyond therapy, and dead (Fig. 1B) . In all treatment arms, the patient could stay in the same state with stable disease, enter a durable response (remission), progress to further chemotherapy, die of adverse effects of therapy, die of cancer, or die of age-and sex-related mortality. All patients failing the first-line treatment were assumed to proceed to a second line. Because there are not yet published data for checkpoint inhibitors for untreated MSI-H/dMMR patients, we used survival data from the CheckMate 142 trial and assumed that outcomes in the first-line setting would be at least the same as (if not better than) outcomes in the third-line setting. We generated a base-case model that included a durable response and a conservative model that did not. For our first-line chemotherapy arm, we used data from the mFOLFOX6 and cetuximab arm of the Cancer and Leukemia Group B (CALGB)/Southwest Oncology Group (SWOG) 80405 trial. 9 Costs and utilities were derived in the same way used for the third-line analysis. The cost of second-line chemotherapy and beyond was based on the cost of FOLFIRI with cetuximab.
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RESULTS
Third-Line Therapy Results
The results of the base-case analysis are presented in Table 2 . For the third-line therapy analysis, ipilimumab and nivolumab was the most effective strategy, but trifluridine and tipiracil was the cost-effective strategy as plotted on the efficiency frontier ( Fig. 2A) . A probabilistic sensitivity analysis of the base-case model found that trifluridine and tipiracil was the cost-effective therapy in 98% of 1000 microsimulations (Fig. 2B ). Trifluridine and tipiracil was also the cost-effective strategy in the conservative model. Reducing the duration of maintenance nivolumab to only 2 years (as with pembrolizumab for non-small cell lung cancer) did change the optimal therapy with respect to cost-effectiveness. At the efficiency frontier, ipilimumab and nivolumab weakly dominated nivolumab monotherapy, and the combination therapy was costeffective in comparison with trifluridine and tipiracil with an ICER of $22,700/QALY. A sensitivity analysis found that ipilimumab and nivolumab would also become the cost-effective strategy if the drug pricing of (Fig. 2C ). Nivolumab and ipilimumab and nivolumab remained more effective than trifluridine and tipiracil across the defined ranges in our deterministic sensitivity analyses.
First-Line Therapy Results
The results of the base-case analysis are presented in Table 2 . For first-line therapy, ipilimumab and nivolumab was the most effective strategy, but neither checkpoint blockade-based therapy was cost-effective in comparison with mFOLFOX6 and cetuximab, as plotted on the efficiency frontier (Fig. 3A) . Reducing the duration of maintenance nivolumab to 2 years actually made mFOL-FOX6 and cetuximab the most expensive treatment strategy; it was strongly dominated (more expensive and less effective). Ipilimumab and nivolumab was cost-effective in comparison with nivolumab (ICER, $6800/QALY). Ipilimumab and nivolumab was also cost-effective if the drug pricing of nivolumab were decreased by approximately half to $3000 per dose (about $14/mg of drug). A sensitivity analysis did not find any changes in parameters by which mFOLFOX6 and cetuximab became more effective than either checkpoint inhibitor therapy or by which nivolumab became more effective than ipilimumab and nivolumab. The cost of mFOLFOX6 and bevacizumab was studied in the chemotherapy drug cost sensitivity analysis and did not change the optimal strategy of any model. The probabilistic sensitivity analysis of the base-case model found that mFOLFOX6 and cetuximab was the most cost-effective therapy in 93% of 1000 microsimulations (Fig. 3B) . At a WTP higher than $180,000/QALY, ipilimumab and nivolumab would become the most cost-effective treatment (Fig. 3C ).
DISCUSSION
Our modeling analyses have found that ipilimumab and nivolumab is the most effective strategy for MSI-H/ dMMR mCRC in both the third-and first-line settings, even in conservative modeling scenarios without a durable response. For the third-line setting, ipilimumab and nivolumab was superior to trifluridine and tipiracil with respect to overall survival and QALYs, with gains of 3 (conservative model) to 10 years (base-case model) of overall survival. Similarly, ipilimumab and nivolumab was the preferred therapy in the first-line setting, with gains of 1.5 to 8 years of overall survival. Ipilimumab and nivolumab was preferred over nivolumab, even when we took into account the higher rates and grades of toxicities, with respect to both overall and quality-adjusted survival. This was primarily due to 2 factors: overall survival with ipilimumab and nivolumab was longer, and patients were more likely to avoid chemotherapy, which had the highest incidence of adverse effects and disutilities in our model. With respect to cost, however, neither ipilimumab and nivolumab nor nivolumab alone was cost-effective. This was driven by the long-term cost of nivolumab maintenance in responders. Further investigations are needed to investigate whether MSI-H/dMMR mCRC can be treated with a finite course of checkpoint blockade, such as in non-small cell lung cancer. 35 With a reduction in the treatment time to 2 years, ipilimumab and nivolumab was the cost-effective strategy with an ICER well under the accepted WTP threshold of $100,000.
Our model has several limitations. This was not an analysis of a randomized clinical trial but rather was a comparison between 2 nonrandomized arms of a phase 2 trial (CheckMate 142) and a separate phase 3 trial for trifluridine and tipiracil. The CheckMate 142 data were published with fewer than 100 patients in each arm and a short follow-up. Because we extrapolated the progression-free and overall survival curves from these studies, uncertainty at the tail of the curve could have large implications for the model. Encouragingly, results from an additional 6 months of follow-up for the nivolumab monotherapy arm are similar to those of the initial reports. 7 In addition, our conservative model, which assumed no durable remission, also found the checkpoint inhibitors more effective with ICERs similar to the base case. The true efficacy of checkpoint inhibitors is likely between our conservative and base-model results. Updated analyses should be performed as more data accrue to generate a more reliable survival estimate.
Not all treatments for mCRC were included in our model. Pembrolizumab was not in our analysis because it was not included in the CheckMate 142 trial. However, because nivolumab and pembrolizumab are both antiprogrammed death 1 antibodies, their mechanism and efficacy are expected to be the same, and so we felt that a study examining nivolumab would also be applicable to pembrolizumab. For the first-line chemotherapy arm, although bevacizumab is more commonly used in rightsided cancers, cetuximab was chosen because it is more expensive than bevacizumab; thus, mFOLFOX6 and cetuximab is a more stringent comparator for the costeffectiveness of the checkpoint inhibitors.
Cancer January 15, 2019 In addition, because of the lack of large studies of MSI-H/dMMR mCRC, we included microsatellite instability/mismatch repair status-unknown and microsatellite stable/mismatch repair-intact cohorts of mCRC in our model to estimate the response to chemotherapy. Because only approximately 4% of all patients with mCRC are MSI-H/dMMR, our population of interest was significantly underrepresented in the RECOURSE and CALGB/SWOG 80405 trials. 47, 48 Because MSI-H/ dMMR mCRC is less responsive to chemotherapy, using these trials biased our results in favor of chemotherapy. Despite this bias, our model still finds checkpoint inhibitor-based therapy more effective than chemotherapy.
Another limitation of the model was uncertainty regarding the incidence, timing, disutilities, and cost of checkpoint inhibitor drug toxicity. Estimates of the incidence and timing of adverse events are largely based on experience with ipilimumab alone. 38, 39 We relied on data from the European Society for Medical Oncology guidelines to estimate the timing of peak ipilimumab and nivolumab toxicities and peak nivolumab toxicities. No robust data are available describing the probability of immune toxicities over the long term; therefore, we relied on an expert-opinion estimate of 5% of all toxicities occurring outside the peak period for as long as patients remained on therapy. Further data are needed to better inform this estimate; however, changes in the probability of long-term toxicities did not change the optimal therapy in the model. Finally, disutilities and costs were assigned to drug toxicities on the basis of limited data, and further health utility measures and cost estimates of patients undergoing immunotherapy are needed. Despite these uncertainties, our sensitivity analysis did not find any changes in utilities or costs of adverse events that changed the optimal strategy. A significant limitation of the first-line model was the assumption that untreated patients would have outcomes at least as robust as those with third-line therapy. Although we suspect that this is true because these patients are earlier in their disease course and have not experienced immunosuppression from chemotherapy, no clinical trial data are yet available. An updated analysis including these results should be performed once they are available.
Finally, the premise of our 2-year limited treatment model was based on data for non-small cell lung cancer. It is unknown whether the biology of this cancer and the biology of MSI-H/dMMR colon cancers is similar enough that treatment for 2 years for colon cancer would be similarly effective. In conclusion, our modeling analysis found ipilimumab and nivolumab to be superior to nivolumab and to trifluridine and tipiracil for the third-line treatment of MSI-H/dMMR mCRC with respect to overall survival and QALYs. Similarly, ipilimumab and nivolumab were more effective in the first-line setting than nivolumab or mFOLFOX6 and cetuximab. Despite dramatic improvements in efficacy, checkpoint inhibitors remain cost-ineffective in comparison with chemotherapy because of the cost of maintenance nivolumab. Clinical trials exploring the efficacy of limiting nivolumab maintenance therapy should be performed.
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